D) Baseline PET/CT (right panel): The fused ��-Nicotinamide research buy PET/CT demonstrates increased FDG activity in the enlarged right adrenal gland. E) Follow-up PET/CT: The fused PET/CT four months after baseline shows a decrease in FDG activity of the right adrenal gland. Note the corresponding decrease in size also. As seen in Table 3, sixteen

patients were evaluable for response by RECIST criteria. A complete response was observed in a patient with S3I-201 hormone-refractory breast cancer metastatic to the adrenal gland and bone (Figure 3), which lasted 11 months. A partial response was observed in a patient with hormone-refractory breast cancer metastatic to bone and liver, which lasted 13.5 months. Five patients had stable disease for +34.1 months (thyroid cancer with biopsy-proven lung metastases), 6.0 months (mesothelioma metastatic to the abdomen), 5.1 months (non-small JQ1 chemical structure cell lung cancer), and 4.1 months (pancreatic cancer with biopsy-proven liver metastases). As of April 1, 2009 two patients are still receiving experimental treatment and four patients are alive. Table 3 Independent review of best response (N = 16) according to RECIST criteria Best response No % Complete response* 1 3.6 Partial

response** 1 3.6 Stable disease*** 5 28.6 Progressive disease**** 9 21.4 Not available for response assessment 12 60.7 * Duration of the complete response was 11 months (breast cancer metastatic to bone and adrenal gland) ** Duration of the partial response was 13.5 months (breast cancer metastatic to bone and liver) *** Duration of stable disease was +34.1 months (thyroid cancer metastatic to lung), 6.0 months (mesothelioma metastatic to abdomen), 5.1 months (Non-small cell lung

cancer), 4.1 months (pancreatic cancer metastatic to liver), and 4.0 months (leiomyosarcoma metastatic to liver). **** One patient with ovarian cancer had progressive disease while receiving 26 frequencies. She has now stable disease and has been receiving amplitude-modulated electromagnetic fields for +50.5 months (Figure 2). Not included is a patient with breast cancer metastatic to bone and liver with a near complete response who started systemic chemotherapy with docetaxel and bevacizumab within ROS1 4 weeks of experimental treatment initiation. Adverse and beneficial reactions No patients receiving experimental therapy reported any side effect of significance and no patient discontinued treatment because of adverse effects. Three patients (10.7%) reported grade I fatigue after receiving treatment. One patient (3.6%) reported grade I mucositis after long-term use (26 months) of the experimental device and concomitant chemotherapy. Two patients with severe bony pain prior to initiation of experimental treatment reported significant symptomatic improvement. Both patients had breast cancer metastatic to the skeleton.